SOPHiA GENETICS (SOPH) AI Stock Analysis

• Market Cap: $349.41M
• Dividend Yield: N/A
• Average Volume (3M): 100.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 13.66%
• EPS Growth: -2.65%
• Country: US
• Employees: 423
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.30
• Shares Outstanding: 67,847,060
• 10 Day Avg. Volume: 137,858
• 30 Day Avg. Volume: 100,949
• PEG Ratio: 0.15
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 3.11
• P/FCF Ratio: -3.98
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: 2.42
• Enterprise Value/Gross Profit: 3.59
• Enterprise Value/Ebitda: -3.07
• 1Y Price Target: $7.00
• Price Target Upside: 33.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $5.00 ▼(-4.76% Downside)

SOPHiA GENETICS' overall stock score is primarily influenced by its financial performance challenges, including profitability and cash flow issues. While technical analysis shows positive momentum, valuation concerns due to ongoing losses weigh heavily. The earnings call highlights strong growth and strategic initiatives, but these are not enough to offset the financial challenges.

Positive Factors

Revenue Growth

Sustained revenue growth indicates strong market demand and effective customer acquisition strategies, enhancing long-term business viability.

U.S. Market Expansion

Expansion in the U.S. market strengthens SOPHiA GENETICS' competitive position and diversifies its revenue base, supporting future growth.

Innovation and AI Development

Innovative AI tools enhance product offerings, potentially improving diagnostic accuracy and attracting more customers, driving long-term growth.

Negative Factors

Operating Loss and Cash Burn

Persistent operating losses and increased cash burn could strain financial resources, challenging the company's ability to sustain operations.

Profitability Challenges

Continued profitability issues may limit reinvestment in growth initiatives and hinder long-term financial health.

Legal and Currency Challenges

Legal and currency challenges increase operational costs and financial uncertainty, potentially affecting future profitability and strategic plans.

SOPHiA GENETICS Business Overview & Revenue Model

Company Description

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

How the Company Makes Money

SOPHiA GENETICS generates revenue through several key streams, primarily focusing on software-as-a-service (SaaS) solutions and genomic data analysis services. The company charges fees for access to its SOPHiA DDM™ platform, which includes subscription fees, pay-per-use models, and service contracts with hospitals, laboratories, and research institutions. Additionally, SOPHiA GENETICS collaborates with pharmaceutical companies in companion diagnostics, where they provide genomic analysis services to support drug development and clinical trials, often receiving funding or revenue-sharing agreements in return. Strategic partnerships with healthcare providers and research organizations further enhance its revenue potential by expanding its market reach and driving adoption of its platform in clinical settings.

SOPHiA GENETICS Financial Statement Overview

Summary

SOPHiA GENETICS demonstrates revenue growth and stable gross margins but faces significant profitability and cash flow challenges. The balance sheet shows manageable leverage, yet negative returns on equity. To improve its financial standing, the company must address its operational inefficiencies and enhance cash flow generation.

Income Statement

SOPHiA GENETICS shows a consistent revenue growth trend, with a 5.18% increase in TTM. However, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins. The gross profit margin remains relatively stable, indicating efficient cost management, but the persistent negative net income and EBIT suggest ongoing operational challenges.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.83 in TTM, indicating manageable leverage. However, the return on equity is negative, highlighting profitability issues. The equity ratio suggests a stable capital structure, but the company needs to improve its returns to enhance financial health.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, with a decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow situation requires improvement to support sustainable operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	73.30M	65.17M	62.37M	47.56M	40.45M	28.40M
Gross Profit	49.49M	43.94M	42.91M	31.25M	25.22M	17.69M
EBITDA	-57.84M	-50.76M	-69.57M	-81.38M	-69.24M	-37.99M
Net Income	-74.98M	-62.49M	-78.98M	-87.45M	-73.67M	-39.34M
Balance Sheet
Total Assets	163.46M	155.31M	206.16M	243.84M	320.17M	132.12M
Cash, Cash Equivalents and Short-Term Investments	81.61M	80.23M	123.25M	178.61M	265.32M	97.34M
Total Debt	63.37M	30.03M	18.60M	16.74M	13.06M	7.25M
Total Liabilities	102.77M	58.82M	54.71M	43.71M	44.77M	31.61M
Stockholders Equity	60.69M	96.49M	151.44M	200.13M	275.40M	100.51M
Cash Flow
Free Cash Flow	-43.87M	-51.00M	-57.80M	-80.47M	-64.61M	-34.93M
Operating Cash Flow	-38.36M	-42.82M	-48.58M	-70.09M	-57.94M	-31.73M
Investing Cash Flow	-7.11M	-8.18M	8.32M	41.97M	-56.93M	-24.32M
Financing Cash Flow	29.99M	11.59M	-2.82M	-1.57M	237.77M	107.05M

SOPHiA GENETICS Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOPH, the sentiment is Positive. The current price of 5.25 is above the 20-day moving average (MA) of 4.83, above the 50-day MA of 4.70, and above the 200-day MA of 3.71, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 59.37 is Neutral, neither overbought nor oversold. The STOCH value of 64.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOPH.

SOPHiA GENETICS Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WGS	59 Neutral	$3.45B	1,821.56	0.84%	―	50.50%	―
OMDA	56 Neutral	$897.57M	-33.33	―	―	50.51%	50.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SOPH	51 Neutral	$349.41M	-4.62	-86.09%	―	13.66%	-2.65%
DH	49 Neutral	$348.47M	-1.47	-47.69%	―	-5.30%	46.01%
SDGR	44 Neutral	$1.35B	-7.62	-45.67%	―	32.90%	1.85%
ZCMD	43 Neutral	$13.96M	-2.81	-8.96%	―	-24.64%	92.19%

SOPHiA GENETICS Corporate Events

SOPHiA GENETICS Announces CEO Transition and Strong Preliminary 2025 Results

On January 12, 2026, SOPHiA GENETICS announced a planned leadership transition, promoting President Ross Muken to Chief Executive Officer effective July 1, 2026, succeeding co-founder and current CEO Dr. Jurgi Camblong, who is expected to move into the role of Executive Chairman of the Board following the company’s June 2026 annual general meeting. The company also released preliminary, unaudited financial figures for the fourth quarter and full year ended December 31, 2025, indicating at least $21 million in quarterly revenue, up about 20% year over year, and approximately $77 million in annual revenue, up about 18%, alongside record activity on its SOPHiA DDM platform with more than 391,000 analyses performed in 2025; these estimates underscore continued growth in usage and revenue but remain subject to adjustment as year-end closing and audit procedures are completed.

The most recent analyst rating on (SOPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.

SOPHiA GENETICS Posts Strong 2025 Preliminary Results and Sets CEO Transition for 2026

On January 12, 2026, SOPHiA GENETICS reported strong preliminary, unaudited results for 2025, with full-year revenue of about $77 million, up roughly 18% year-on-year, and more than 391,000 analyses performed on its SOPHiA DDM™ platform, including over 105,000 analyses and at least $21 million in revenue in the fourth quarter alone. The company signaled continued momentum by issuing 2026 revenue guidance of $92–94 million, implying 20–22% growth, alongside an expected adjusted EBITDA loss of $29–32 million, and outlined a significant leadership transition: President Ross Muken, a key architect of its commercial transformation since joining as CFO in 2021, will become CEO on July 1, 2026, while co-founder and current CEO Jurgi Camblong will move to the role of Executive Chairman, with long-time executive Kevin Puylaert stepping up as Chief Sales Officer in January 2026, underscoring a planned succession aimed at sustaining growth and strengthening the company’s position in AI-powered precision medicine.

The most recent analyst rating on (SOPH) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.

SOPHiA GENETICS Reports Financial Results for Q3 2025

On November 4, 2025, SOPHiA GENETICS SA released its unaudited interim condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a revenue increase compared to the previous year, but it also experienced a significant loss for the period. This financial update reflects the company’s ongoing investment in research and development, as well as selling and marketing efforts, which are crucial for its growth and competitive positioning in the biotechnology sector.

The most recent analyst rating on (SOPH) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on SOPHiA GENETICS stock, see the SOPH Stock Forecast page.